Secondary Osteoporosis: Underlying Disease and the Risk for Glucocorticoid-Induced Osteoporosis

Clinical Therapeutics

Volumn 26, Issue 1, 2004, Pages 1-14

  Boling, Eugene P ^a,b  

^a LOMA LINDA UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Alendronate; Glucocorticoids; Risedronate; Secondary osteoporosis

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CYCLOSPORIN; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; PARATHYROID HORMONE[1-34]; PREDNISOLONE; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

ALLERGIC RHINITIS; ARTHRALGIA; ASTHMA; BACKACHE; BILIARY CIRRHOSIS; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CHRONIC DISEASE; CHRONIC GLOMERULONEPHRITIS; CHRONIC LIVER DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CROHN DISEASE; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; ENTERITIS; ESOPHAGUS ULCER; EXERCISE; FRACTURE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HUMAN; KIDNEY DISEASE; LIFESTYLE; LIVER DISEASE; LONG TERM CARE; LUNG DISEASE; MEDLINE; NONHUMAN; NUTRITION; OSTEOLYSIS; OSTEOPENIA; PATIENT MOBILITY; PEPTIC ULCER; POSTMENOPAUSE OSTEOPOROSIS; PREGNANCY; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSPLANTATION; ULCERATIVE COLITIS; UPPER GASTROINTESTINAL TRACT; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION; WEIGHT BEARING;

EID: 1242294541     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90001-X     Document Type: Review

References (88)

1. Blair MM, Carson DS, Barrington R. Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis. J Fam Pract. 2000;49:839-848.
2. Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: A cross sectional study. BMJ. 1996;313:344-346.
3. Hodgson SF, Dickson ER, Eastell R, et al. Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis. Bone. 1993; 14:819-827.
4. Ardizzone S, Bollani S, Bettica P, et al. Altered bone metabolism in inflammatory bowel disease: There is a difference between Crohn's disease and ulcerative colitis. J Intern Med. 2000;247:63-70.
5. Klaus J, Armbrecht G, Steinkamp M, et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut. 2002;51:654-658.
6. Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: Results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum. 2000;43:522-530.
7. Petri M. Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: An update. Arthritis Care Res. 1995;8:137-145.
8. Sinigaglia L, Varenna M, Binelli L, et al. Determinants of bone mass in systemic lupus erythematosus: A cross sectional study on premenopausal women. J Rheumatol. 1999;26:1280-1284.
9. Saag KG. Low-dose corticosteroid therapy in rheumatoid arthritis: Balancing the evidence. Am J Med. 1997;103:S31-S39.
10. Baxter JD. Advances in glucocorticoid therapy. Adv Intern Med. 2000;45:317-349.
11. Cunnane G, Lane NE. Steroid-induced osteoporosis in systemic lupus erythematosus. Rheum Dis Clin North Am. 2000;26:311-329, vi-vii.
12. Goldstein MF, Fallon JJ Jr, Harning R. Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease. Chest. 1999;116:1733-1749.
13. Rackoff PJ, Rosen CJ. Pathogenesis and treatment of glucocorticoid- induced osteoporosis. Drugs Aging. 1998;12:477-484.
14. Adachi JD, Bensen WG, Bell MJ, et al. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol. 1997;36:255-259.
15. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999;42:2309-2318.
16. Reid IR. Glucocorticoid-induced osteoporosis. Baillieres Best Pract Res Clin Endocrinol Metab. 2000;14:279-298.
17. van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993-1000.
18. Reid IR. Glucocorticoid osteoporosis - mechanisms and management. Eur J Endocrinol. 1997;137:209-217.
19. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med. 1983;309:265-268.
20. Michel BA, Bloch DA, Fries JF. Predictors of fractures in early rheumatoid arthritis. J Rheumatol. 1991;18: 804-808.
21. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: Pathogenesis and management. Ann Intern Med. 1990;112:352-364.
22. van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: Relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39: 1383-1389.
23. Ruegsegger P, Medici TC, Anliker M. Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol. 1983;25:615-620.
24. Libanati CR, Baylink DJ. Prevention and treatment of glucocorticoid- induced osteoporosis. A pathogenetic perspective. Chest. 1992;102:1426-1435.
25. Smith BJ, Phillips PJ, Heller RF. Asthma and chronic obstructive airway diseases are associated with osteoporosis and fractures: A literature review. Respirology. 1999;4:101-109.
26. Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: Lessons for the new millennium. Drug Saf. 2000;23:11-33.
27. Bonala SB, Reddy BM, Silverman BA, et al. Bone mineral density in women with asthma on long-term inhaled corticosteroid therapy. Ann Allergy Asthma Immunol. 2000;85:495-500.
28. Sorkness CA. Establishing a therapeutic index for the inhaled corticosteroids: Part II. Comparisons of systemic activity and safety among different inhaled corticosteroids. J Allergy Clin Immunol. 1998;102:S52-S64.
29. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med. 1999;159:941-955.
30. Tattersfield AE, Town GI, Johnell O, et al. Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years. Thorax. 2001; 56:272-278.
31. Wong CA, Walsh LJ, Smith CJ, et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet. 2000;355:1399-1403.
32. Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in pre-menopausal women. N Engl J Med. 2001;345:941-947.
33. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Hillsborough, NJ: Excerpta Medica; 2003.
34. Thompson JM, Modin GW, Arnaud CD, Lane NE. Not all postmenopausal women on chronic steroid and estrogen treatment are osteoporotic: Predictors of bone mineral density. Calcif Tissue Int. 1997;61:377-381.
35. National Institutes of Health Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: Highlights of the conference. South Med J. 2001;94:569-573.
36. Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut. 2002;50(Suppl 1):i1-i9.
37. Diamond T, Stiel D, Lunzer M, et al. Osteoporosis and skeletal fractures in chronic liver disease. Gut. 1990; 31:82-87.
38. Wolfhagen FH, van Buuren HR, Vleggaar FP, Schalm SW Management of osteoporosis in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol. 2000; 14:629-641.
39. Bonkovsky HL, Hawkins M, Steinberg K, et al. Prevalence and prediction of osteopenia in chronic liver disease. Hepatology. 1990;12:273-280.
40. Ormarsdottir S, Ljunggren O, Mallmin H, et al. Low body mass index and use of corticosteroids, but not cholestasis, are risk factors for osteoporosis in patients with chronic liver disease. J Hepatol. 1999;31:84-90.
41. Pigot F, Roux C, Chaussade S, et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci. 1992;37:1396-1403.
42. Robinson RJ, al-Azzawi F, Iqbal SJ, et al. Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci. 1998;43:2500-2506.
43. Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med. 2000;133:795-799.
44. Bernstein CN, Leslie WD. The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol. 2003;15:857-864.
45. Scharla SH, Minne HW, Lempert UG, et al. Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis). Exp Clin Endocrinol. 1994; 102:44-49.
46. Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. J Intern Med. 1996;239:131-137.
47. Laan RF, Jansen TL, van Riel PL. Glucocorticosteroids in the management of rheumatoid arthritis. Rheumatology (Oxford). 1999;38:6-12.
48. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis. 1995;54:49-52.
49. Tanaka Y, Watanabe K, Suzuki M, et al. Spontaneous production of bone-resorbing lymphokines by B cells in patients with systemic lupus erythematosus. J Clin Immunol. 1989;9:415-420.
50. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am. 1994;20:629-650.
51. Jardinet D, Lefebvre C, Depresseux G, et al. Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: Deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology (Oxford). 2000;39:389-392.
52. Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58:396-399.
53. Taal MW, Masud T, Green D, Cassidy MJ. Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant. 1999;14:1922-1928.
54. Stein MS, Packham DK, Ebeling PR, et al. Prevalence and risk factors for osteopenia in dialysis patients. Am J Kidney Dis. 1996;28:515-522.
55. Kraut JA. Disturbances of acid-base balance and bone disease in end-stage renal disease. Semin Dial. 2000;13: 261-266.
56. Yonemura K, Kimura M, Miyaji T, Hishida A. Short-term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patients with chronic glomerulonephritis. Calcif Tissue Int. 2000;66: 123-128.
57. National Asthma Education Prevention Program Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, Md: National Institutes of Health; 1997.
58. Iqbal F, Michaelson J, Thaler L, et al. Declining bone mass in men with chronic pulmonary disease: Contribution of glucocorticoid treatment, body mass index, and gonadal function. Chest. 1999;116:1616-1624.
59. McEvoy CE, Ensrud KE, Bender E, et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:704-709.
60. Praet JP, Peretz A, Rozenberg S, et al. Risk of osteoporosis in men with chronic bronchitis. Osteoporos Int. 1992;2:257-261.
61. Villareal MS, Klaustermeyer WB, Hahn TJ, Gordon EH. Osteoporosis in steroid-dependent asthma. Ann Allergy Asthma Immunol. 1996;76:369-372.
62. Shane E, Silverberg SJ, Donovan D, et al. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med. 1996;101:262-269.
63. van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res. 2001;16:581-588.
64. Braith RW, Howard C, Fricker FJ, et al. Glucocorticoid-induced osteopenia in adolescent heart transplant recipients. J Heart Lung Transplant. 2000;19:840-845.
65. Cayco AV, Wysolmerski J, Simpson C, et al. Posttransplant bone disease: Evidence for a high bone resorption state. Transplantation. 2000;70:1722-1728.
66. Spira A, Gutierrez C, Chaparro C, et al. Osteoporosis and lung transplantation: A prospective study. Chest. 2000;117:476-481.
67. Giannini S, Nobile M, Ciuffreda M, et al. Long-term persistence of low bone density in orthotopic liver transplantation. Osteoporos Int. 2000;11:417-424.
68. Heaf J, Tvedegaard E, Kanstrup IL, Fogh-Andersen N. Bone loss after renal transplantation: Role of hyperparathyroidism, acidosis, cyclosporine and systemic disease. Clin Transplant. 2000;14:457-463.
69. Porayko MK, Wiesner RH, Hay JE, et al. Bone disease in liver transplant recipients: Incidence, timing, and risk factors. Transplant Proc. 1991;23:1462-1465.
70. Kokado Y, Takahara S, Ichimaru N, et al. Factors influencing vertebral bone density after renal transplantation. Transpl Int. 2000;13(Suppl 1):S431-S435.
71. Rodino MA, Shane E. Osteoporosis after organ transplantation. Am J Med. 1998;104:459-469.
72. McDonald JA, Dunstan CR, Dilworth P, et al. Bone loss after liver transplantation. Hepatology. 1991;14:613-619.
73. Leidig-Bruckner G, Hosch S, Dodidou P, et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: A follow-up study. Lancet. 2001;357:342-347.
74. Eastell R, Dickson ER, Hodgson SF, et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology. 1991;14:296-300.
75. Feller RB, McDonald JA, Sherbon KJ, McCaughan GW. Evidence of continuing bone recovery at a mean of 7 years after liver transplantation. Liver Transpl Surg. 1999;5:407-413.
76. Bell R, Carr A, Thompson P. Managing corticosteroid induced osteoporosis in medical outpatients. J R Coll Physicians Lond. 1997;31:158-161.
77. National Institutes of Health Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-795.
78. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 Update. Arthritis Rheum. 2001;44:1496-1503.
79. Actonel® prescribing information [package insert]. Cincinnati, Ohio: Procter & Gamble Pharmaceuticals; 2002.
80. Fosamax® prescribing information [package insert]. West Point, Pa: Merck & Co, Inc; 2002.
81. Cauley JA, Robbins J, Chen Z, et al, for the Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative randomized trial. JAMA. 2003;290:1729-1738.
82. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res. 2000;15:1006-1013.
83. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000;67:277-285.
84. Saag KG, Emkey R, Schnitzer TJ, et al, for the Glucocorticoid-Induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998;339:292-299.
85. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001;44:202-211.
86. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
87. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30:312-321.
88. Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. Clin Invest. 1998;102:1627-1633.